Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Nanobiotix Declaration of Voting Results & Voting Rights Announcements 2026

Apr 7, 2026

1541_dva_2026-04-07_6a980167-c444-4a37-b06b-eb8928c9d9ad.pdf

Declaration of Voting Results & Voting Rights Announcements

Open in viewer

Opens in your device viewer

NANOBIOTIX

EXPANDING

LIFE

PRESS RELEASE

VOTING RIGHTS AND SHARES CAPITAL OF THE COMPANY

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

Paris, France, April 7, 2026

Market: Euronext Paris / Nasdaq

Euronext Compartment: B

ISIN code: FR0011341205

Nasdaq: NBTX

Bloomberg: NANO:FP

Reuters: NANO.PA

Website: www.nanobiotix.com

Date Number of Shares Outstanding Total number of voting rights
Total voting rights, theoretical1 Total voting rights, exercisable2
March 31, 2026 48,517,630 50,165,132 50,143,014

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company's philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has a subsidiary in Cambridge, Massachusetts (United States).

Nanobiotix is the owner of more than 30 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.


NANOBIOTIX
EXPANDING
LIFE

Contacts

Nanobiotix

Communications Department Investor Relations Department
Brandon Owens Joanne Choi
VP, Communications VP, Investor Relations (US)
+1 (617) 852-4835 +1 (713) 609-3150
[email protected] Ricky Bhajun
Director, Investor Relations (EU)
[email protected]

Media Relations

France – HARDY Global – uncapped
Caroline Hardy Becky Lauer
+33 06 70 33 49 50 +1 (646) 286-0057
[email protected] [email protected]

NBTX
Nasdaq Listed

NANO
LISTED
EURONEXT